Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Changing paradigms in the treatment of malignant pheochromocytoma.

Grogan RH, Mitmaker EJ, Duh QY.

Cancer Control. 2011 Apr;18(2):104-12. Review.

2.

Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.

Santarpia L, Habra MA, Jiménez C.

Horm Metab Res. 2009 Sep;41(9):680-6. doi: 10.1055/s-0029-1214381. Epub 2009 Apr 2. Review.

PMID:
19343618
3.

Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.

Andersen KF, Altaf R, Krarup-Hansen A, Kromann-Andersen B, Horn T, Christensen NJ, Hendel HW.

Cancer Treat Rev. 2011 Apr;37(2):111-9. doi: 10.1016/j.ctrv.2010.07.002. Epub 2010 Aug 2. Review.

PMID:
20675056
4.

The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.

Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC.

J Endocrinol Invest. 1997 Dec;20(11):648-58. Review.

PMID:
9492103
5.

[Malignant pheochromocytoma].

Tanabe A, Tsuiki M, Takano K, Naruse M.

Nihon Rinsho. 2006 May 28;Suppl 1:739-43. Review. Japanese. No abstract available.

PMID:
16776263
6.

Management of malignant phaeochromocytoma.

El-Modir A, Awwad S.

Clin Oncol (R Coll Radiol). 2002 Jun;14(3):261. No abstract available.

PMID:
12109835
7.

Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas.

Korpershoek E, Stobbe CK, van Nederveen FH, de Krijger RR, Dinjens WN.

Endocr Relat Cancer. 2010 Jun 25;17(3):653-62. doi: 10.1677/ERC-10-0072. Print 2010 Sep.

8.

Recent developments in the therapy of phaeochromocytoma.

Chew SL.

Expert Opin Investig Drugs. 2004 Dec;13(12):1579-83. Review.

PMID:
15566315
9.

Pheochromocytoma treated with I-131 MIBG.

Khiari K, Hadj Ali I, Lakhoua Y, McHirgui N, Hammami H, Ben Abdallah N.

Tunis Med. 2013 Feb;91(2):157-8. No abstract available.

PMID:
23526285
10.

Pheochromocytoma: current approaches and future directions.

Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, Sidhu SB.

Oncologist. 2008 Jul;13(7):779-93. doi: 10.1634/theoncologist.2008-0043. Epub 2008 Jul 10. Review.

11.

Pheochromocytoma: presentation, diagnosis and treatment.

Reisch N, Peczkowska M, Januszewicz A, Neumann HP.

J Hypertens. 2006 Dec;24(12):2331-9. Review.

PMID:
17082709
12.

Results of [131I]metaiodobenzylguanidine therapy administered to three patients with malignant pheochromocytoma.

Schvartz C, Gibold C, Vuillemin B, Delisle MJ.

J Nucl Biol Med. 1991 Oct-Dec;35(4):305-7.

PMID:
1823842
13.

Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.

Suh I, Shibru D, Eisenhofer G, Pacak K, Duh QY, Clark OH, Kebebew E.

Ann Surg. 2009 Dec;250(6):983-90. doi: 10.1097/SLA.0b013e3181b248bb.

PMID:
19661783
14.

Paragangliomas: etiology, presentation, and management.

Joynt KE, Moslehi JJ, Baughman KL.

Cardiol Rev. 2009 Jul-Aug;17(4):159-64. doi: 10.1097/CRD.0b013e3181a6de40. Review.

PMID:
19525677
15.

Session on the role of [131I]metaiodobenzylguanidine in the treatment of malignant phaeochromocytoma. Chairmen's report.

Ackery DM, Troncone L.

J Nucl Biol Med. 1991 Oct-Dec;35(4):318-20. No abstract available.

PMID:
1823846
16.

[Bilateral pheochromocytoma. Genetics and treatment].

Mirallié E, Cariou B, Kraeber-Bodéré F.

Ann Chir. 2005 Apr;130(4):273-6. Review. French. No abstract available.

PMID:
15847867
17.

[Benign and malignant pheochromocytoma].

Lehnert H, Hahn K, Dralle H.

Internist (Berl). 2002 Feb;43(2):196, 199-209. Review. German. No abstract available.

PMID:
11963757
18.

Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry.

Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G.

Endocr Relat Cancer. 2008 Mar;15(1):343-50. doi: 10.1677/ERC-07-0188.

19.

The management of benign and malignant pheochromocytoma and abdominal paraganglioma.

Edström Elder E, Hjelm Skog AL, Höög A, Hamberger B.

Eur J Surg Oncol. 2003 Apr;29(3):278-83.

PMID:
12657240
20.

(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy.

Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, Orunesu E, Luksch R, Bombardieri E.

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):100-13.

Supplemental Content

Support Center